Why Moderna, Inc. (MRNA) Stock Rose 5.8% on Nov 9, 2026
What happened
Moderna surged 9.2% to $277.58 after Piper Sandler raised its price target to $305 per share, citing blockbuster potential for the melanoma vaccine candidate intismeran in combination with Merck's Keytruda. The move builds on momentum from Moderna's late-October Q3 results, which included a surprise profit, $1.31 billion revenue (up 29% year-over-year), and a raised full-year 2026 revenue outlook to 15–25% growth from a prior 10% ceiling, per Zacks earnings call highlights and Yahoo Finance.
Moderna earnings scheduled for 2027-02-12 (date not yet confirmed); monitor for intismeran regulatory or clinical readouts alongside Q4 revenue and COVID-19 vaccine demand trends.
Other developments that session
Moderna expands beyond COVID vaccines into cancer treatment with promising Phase 3 personalized vaccine data.
Moderna raised 2026 revenue guidance to 15-25% growth and Intismeran showed 42% reduction in melanoma recurrence/death.
Frequently asked questions
Why did Moderna, Inc. (MRNA) stock rise on Nov 9, 2026?
Moderna surged 9.2% to $277.58 after Piper Sandler raised its price target to $305 per share, citing blockbuster potential for the melanoma vaccine candidate intismeran in combination with Merck's Keytruda. The move builds on momentum from Moderna's late-October Q3 results, which included a surprise profit, $1.31 billion revenue (up 29% year-over-year), and a raised full-year 2026 revenue outlook to 15–25% growth from a prior 10% ceiling, per Zacks earnings call highlights and Yahoo Finance.
How much did MRNA stock rise on Nov 9, 2026?
MRNA rose 5.8% during the Nov 9, 2026 trading session.